TriangleFOR PATIENTS · SOURCE READING
Treatment of Childhood Acute Promyelocytic Leukemia
Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 5, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Named disease sections within a broader NCI patient summary Only the named source sections and descendants are joined. Parent source is broader; original patient terminology and grade/setting constraints must remain visible.
For information about the treatments listed below, see the Treatment Option Overview section.
Source links and citations
Treatment of newly diagnosed childhood acute promyelocytic leukemia (APL) may include the following:
Source links and citations
Tretinoin with arsenic trioxide.
Source links and citations
Tretinoin plus chemotherapy with or without arsenic trioxide.
Source links and citations
Supportive care.
Source links and citations
Treatment of childhood APL during the remission phase (consolidation/intensification therapy) may include the following:
Source links and citations
Tretinoin with arsenic trioxide.
Tretinoin plus chemotherapy with or without arsenic trioxide.
Treatment of childhood APL during the remission phase (maintenance therapy) may include the following:
Source links and citations
Tretinoin with combination chemotherapy.
Source links and citations
Treatment of recurrent childhood APL may include the following:
Source links and citations
Arsenic trioxide therapy with or without tretinoin.
Targeted therapy with a monoclonal antibody (gemtuzumab ozogamicin).
Source links and citations
Stem cell transplant using blood stem cells from the patient or a donor.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice